| 
 Englishi  | 
 ÖÐÎÄ  | 
 Englishi  | 
 ÖÐÎÄ  | 
| 
 adenocarcinoma  | 
 ÏÙ¹ÜÉÏÆ¤£¬ÏÙ°©  | 
 malignant meningioma  | 
 ÄÔĤ£¬¶ñÐÔÄÔĤÁö  | 
| 
 adrenal cortical carcinoma  | 
 ÉöÉÏÏÙÆ¤ÖÊ£¬ÉöÉÏÏÙÆ¤Öʰ©  | 
 malignant mesothelioma  | 
 ¼äƤ£¬¶ñÐÔ¼äÆ¤Áö  | 
| 
 Alpha-Iantitrypsin deficiency  | 
 a-¿¹¼××´ÏÙËØÈ±·¦Ö¢  | 
 malignant mixed tumor  | 
 ÍÙÒºÏÙ£¬¶ñÐÔ»ìºÏÁö  | 
| 
 American Joint Committee on Cancer Staging; AJCC  | 
 ÃÀ¹ú°©Ö¢·ÖÆÚÁªºÏίԱ»á  | 
 malignant pheochromocytoma  | 
 ÉöÉÏÏÙËèÖÊ£¬¶ñÐÔÊȸõϸ°ûÁö  | 
| 
 angiosarcoma  | 
 Ѫ¹ÜÄÚÆ¤£¬Ñª¹ÜÈâÁö  | 
 malignant phyllodes tumor  | 
 Èé·¿£¬¶ñÐÔÒ¶×´Áö  | 
| 
 basal cell carcinoma  | 
 »ùµ×ϸ°û£¬»ùµ×ϸ°û°©  | 
 malignant teratoma  | 
 ¶ñÐÔ»ûÌ¥Áö  | 
| 
 breast carcinoma  | 
 ÈéÏÙ°©  | 
 melanoma  | 
 °©Ö¢£¬ºÚËØÁö  | 
| 
 carcinoembryonic antigen; CEA  | 
 °©Åß¿¹Ô  | 
 mesothelioma  | 
 ¼äƤÁö  | 
| 
 carcinoma  | 
 ¶ñÐÔÉÏÆ¤Ö×Áö  | 
 Microinvasive carcinoma  | 
 ΢ÇÖÏ®°©  | 
| 
 Carcinoma in situ  | 
 Ôλ°©  | 
 mild dysplasia  | 
 Çá¶ÈÒìÉú  | 
| 
 catecholamine  | 
 ¶ù²è·Ó°·  | 
 moderate dysplasia  | 
 ÖжÈÒìÉú  | 
| 
 cerebroma  | 
 ÄÔÁö  | 
 moderately differentiated  | 
 Öжȷֻ¯  | 
| 
 chondrosarcoma  | 
 Èí¹Ç£¬Èí¹ÇÈâÁö  | 
 multiple myeIoma  | 
 ¶à·¢ÐÔ¹ÇËèÁö  | 
| 
 choriocarcinoma  | 
 Ì¥ÅÌÉÏÆ¤£¬ÈÞëĤ°©  | 
 myeloma  | 
 ½¬Ï¸°û£¬¹ÇËèÁö  | 
| 
 colon cancer  | 
 ½á³¦°©  | 
 neuroblastoma  | 
 Éñ¾½Úϸ°û£¬Éñ¾Ä¸Ï¸°ûÁö  | 
| 
 Cysticfibrosis  | 
 ÄÒÐÔÏËά±äÐÔ  | 
 neuroblastoma  | 
 Éñ¾Ä¸Ï¸°ûÁö  | 
| 
 direct extension  | 
 Ö±½ÓÂûÑÓ  | 
 neuroblastoma  | 
 Éñ¾Ä¸Ï¸°ûÁö  | 
| 
 dysgerminoma  | 
 ¶ñÐÔÅßÌ¥Áö  | 
 neuron-specific enolase; NSE  | 
 Éñ¾ÌØÒìÐÔÏ©´¼  | 
| 
 Dysplasia  | 
 񓃜  | 
 oma  | 
 Á¼ÐÔÖ×Áö  | 
| 
 Familialhypercholesterolemia  | 
 ¼Ò×åÐÔµ¨¹Ì´¼¹ý¶àÖ¢  | 
 osteosarcoma  | 
 Ó²¹Ç£¬¹ÇÈâÁö  | 
| 
 Fanconi sanemia Fanconi's  | 
 ƶѪ֢  | 
 ova-rian  | 
 Âѳ²°©  | 
| 
 fibrosarcoma  | 
 ÏËά×éÖ¯£¬ÏËάÈâÁö  | 
 poorly differentiated  | 
 ·Ö»¯²»Á¼  | 
| 
 glioma  | 
 Éñ¾½ºÏ¸°û£¬Éñ¾½ºÏ¸°ûÁö  | 
 prostate-specific antigen; PSA  | 
 ǰÁÐÏÙÌØÒìÐÔ¿¹Ô  | 
| 
 hematogenous metastasis  | 
 ѪÐÐ×ªÒÆ  | 
 prostatic acid phosphatase; PAP  | 
 ǰÁÐÏÙËáÐÔÁ×Ëá  | 
| 
 HemophiIia  | 
 ѪÓѲ¡  | 
 prostatic csarcinoma  | 
 ǰÁÐÏÙ°©  | 
| 
 hepatocellular carcinoma; hepatoma  | 
 ¸Îϸ°û£¬¸Îϸ°û°©  | 
 Purine nucleoside phosphorylase deficiency  | 
 æÎÒ÷ºË¿àËáÁ×ËáËáȱ·¦Ö¢  | 
| 
 hepatoma ;liver cancer  | 
 ¸Î°©  | 
 renal cell carcinoma  | 
 ÉöÔàÉÏÆ¤£¬Éöϸ°û°©  | 
| 
 histopathological grading  | 
 ×éÖ¯²¡Àí·Ö»¯  | 
 renaleelI  | 
 Éöϸ°û°©  | 
| 
 human chorionic gonadotropin; HCG  | 
 ÈËÀàÈÞëĤ´ÙÐÔÏÙËØ  | 
 rhabdomyosarcoma  | 
 ºáÎÆ¼¡£¬ºáÎÆ¼¡ÈâÁö  | 
| 
 Hunter'ssyndrome  | 
 ºàÌØÊÏ×ÛºÏÖ¢  | 
 sarcoma  | 
 ¶ñÐÔ¼äÒ¶Ö×Áö  | 
| 
 immature teratoma  | 
 È«ÄÜϸ°û£¬Î´³ÉÊì»ûÌ¥Áö  | 
 SCID  | 
 ÑÏÖØ¸´ºÏÃâÒßȱʧ֢  | 
| 
 Invasive carcinoma  | 
 ÇÖÏ®°©  | 
 seminoma  | 
 Éúֳϸ°û£¬¾«Ï¸°ûÁö  | 
| 
 leiomyosarcoma  | 
 ƽ»¬¼¡£¬Æ½»¬¼¡ÈâÁö  | 
 severe dysplasia  | 
 ÖØ¶ÈÒìÉú  | 
| 
 leukemia  | 
 ÔìѪϸ°û£¬°×Ѫ²¡  | 
 squamous cell carcinoma  | 
 ÁÛ×´ÉÏÆ¤£¬ÁÛ״ϸ°û°©  | 
| 
 leukemia  | 
 ×Ôϸ°ûÁö  | 
 stage  | 
 ÆÚ±ð  | 
| 
 liposarcoma  | 
 Ö¬·¾×éÖ¯£¬Ö¬·¾ÈâÁö  | 
 synovial sarcoma  | 
 »¬Ä¤£¬»¬Ä¤ÈâÁö  | 
| 
 lung cancer  | 
 ·Î°©  | 
 thymic carcinoma  | 
 ÐØÏÙÉÏÆ¤£¬ÐØÏÙ°©  | 
| 
 lymphangiosarcoma  | 
 Áܰ͹ÜÄÚÆ¤£¬Áܰ͹ÜÈâÁö  | 
 transitional cell carcinoma  | 
 ÃÚÄòµÀÉÏÆ¤£¬¹ý¶Éϸ°û°©  | 
| 
 lymphatic metastasis  | 
 ÁܰÍ×ªÒÆ  | 
 tumor marker  | 
 ÁÙ´²¼ìÑ飬º¬Ö×Áö±ê¼Ç  | 
| 
 lymphoma  | 
 ÀàÁܰÍ×éÖ¯£¬ÁܰÍÁö  | 
 undifferentiated  | 
 δ·Ö»¯  | 
| 
 lymphoma  | 
 ÁܰÍÈâÁö  | 
 well differentiated  | 
 ·Ö»¯Á¼ºÃ  | 
| 
 malignant melanoma  | 
 Éñ¾ÍâÅ߲㣬¶ñÐÔºÚÉ«ËØÁö  | 
 ¼Ò×åÐÔÆ¢ÐÔÆ¶Ñª  | 
 Gaucher's²¡  |